Your browser doesn't support javascript.
loading
Etiology-independent activation of the LTß-LTßR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.
Scherr, Anna-Lena; Nader, Luisa; Xu, Kaiyu; Elssner, Christin; Ridder, Dirk A; Nichetti, Federico; Mastel, Manuel; Fritzsche, Sarah; Kelmendi, Eblina; Schmitt, Nathalie; Hoffmeister-Wittmann, Paula; Weiler, Sofia M E; Korell, Felix; Albrecht, Thomas; Schwab, Maximilian; Isele, Hanna; Kessler, Annika; Hüllein, Jennifer; Seretny, Agnieszka; Ye, Liangtao; Urbanik, Toni; Welte, Stefan; Leblond, Anne-Laure; Heilig, Christoph E; Rahbari, Mohammad; Ali, Adnan; Gallage, Suchira; Lenoir, Bénédicte; Wilhelm, Nina; Gärtner, Ulrike; Ogrodnik, Simon J; Springfeld, Christoph; Tschaharganeh, Darjus; Fröhling, Stefan; Longerich, Thomas; Schulze-Bergkamen, Henning; Jäger, Dirk; Brandl, Lydia; Schirmacher, Peter; Straub, Beate K; Weber, Achim; De Toni, Enrico N; Goeppert, Benjamin; Heikenwalder, Mathias; Jackstadt, Rene; Roessler, Stephanie; Breuhahn, Kai; Köhler, Bruno C.
Affiliation
  • Scherr AL; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Nader L; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Xu K; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Elssner C; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Ridder DA; Department of General Pathology, University Hospital Mainz, Mainz, Germany.
  • Nichetti F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Mastel M; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Fritzsche S; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
  • Kelmendi E; Cancer Progression and Metastasis Group, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Schmitt N; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Hoffmeister-Wittmann P; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Weiler SME; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Korell F; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Albrecht T; Department of Radiooncology, University Hospital Heidelberg, Heidelberg, Germany.
  • Schwab M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Isele H; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Kessler A; Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Hüllein J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Seretny A; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Ye L; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Urbanik T; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Welte S; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Leblond AL; Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Heilig CE; Helmholtz-University Group "Cell Plasticity and Epigenetic Remodeling", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Rahbari M; Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich.
  • Ali A; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Gallage S; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Lenoir B; Department of Radiooncology, University Hospital Heidelberg, Heidelberg, Germany.
  • Wilhelm N; Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Zurich, Switzerland.
  • Gärtner U; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Ogrodnik SJ; Department of Translational Medical Oncology, NCT Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Springfeld C; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.
  • Tschaharganeh D; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.
  • Fröhling S; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.
  • Longerich T; Clinical Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
  • Schulze-Bergkamen H; Clinical Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
  • Jäger D; Interfaculty Biomedical Research Facility, University of Heidelberg, Heidelberg, Germany.
  • Brandl L; Division of Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schirmacher P; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Straub BK; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Weber A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • De Toni EN; Helmholtz-University Group "Cell Plasticity and Epigenetic Remodeling", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Goeppert B; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Heikenwalder M; Department of Translational Medical Oncology, NCT Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jackstadt R; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Roessler S; Department of Internal Medicine II, Marien-Hospital, Wesel, Germany.
  • Breuhahn K; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
  • Köhler BC; Institute of Pathology, Medical Faculty, Ludwig-Maximilians-University, Munich, Germany.
Hepatology ; 2023 Nov 02.
Article in En | MEDLINE | ID: mdl-37916976
ABSTRACT
BACKGROUND AND

AIMS:

HCC is the most common primary liver tumor, with an increasing incidence worldwide. HCC is a heterogeneous malignancy and usually develops in a chronically injured liver. The NF-κB signaling network consists of a canonical and a noncanonical branch. Activation of canonical NF-κB in HCC is documented. However, a functional and clinically relevant role of noncanonical NF-κB and its downstream effectors is not established. APPROACH AND

RESULTS:

Four human HCC cohorts (total n = 1462) and 4 mouse HCC models were assessed for expression and localization of NF-κB signaling components and activating ligands. In vitro , NF-κB signaling, proliferation, and cell death were measured, proving a pro-proliferative role of v-rel avian reticuloendotheliosis viral oncogene homolog B (RELB) activated by means of NF-κB-inducing kinase. In vivo , lymphotoxin beta was identified as the predominant inducer of RELB activation. Importantly, hepatocyte-specific RELB knockout in a murine HCC model led to a lower incidence compared to controls and lower maximal tumor diameters. In silico , RELB activity and RELB-directed transcriptomics were validated on the The Cancer Genome Atlas HCC cohort using inferred protein activity and Gene Set Enrichment Analysis. In RELB-active HCC, pathways mediating proliferation were significantly activated. In contrast to v-rel avian reticuloendotheliosis viral oncogene homolog A, nuclear enrichment of noncanonical RELB expression identified patients with a poor prognosis in an etiology-independent manner. Moreover, RELB activation was associated with malignant features metastasis and recurrence.

CONCLUSIONS:

This study demonstrates a prognostically relevant, etiology-independent, and cross-species consistent activation of a lymphotoxin beta/LTßR/RELB axis in hepatocarcinogenesis. These observations may harbor broad implications for HCC, including possible clinical exploitation.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Hepatology Year: 2023 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Hepatology Year: 2023 Type: Article Affiliation country: Germany